Article
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
British journal of clinical pharmacology - 1 Sept 2016
Aminkeng Folefac, Ross Colin J D, Rassekh Shahrad R, Hwang Soomi, Rieder Michael J, Bhavsar Amit P, Smith Anne, Sanatani Shubhayan, Gelmon Karen A, Bernstein Daniel, Hayden Michael R, Amstutz Ursula, Carleton Bruce C
Abstract excerpt
AIMS: Anthracycline-induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline-based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence-based clinical practice recommendations for pharmacogenomic testing to further individualize therapy based on ACT risk....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.